Lucid Diagnostics (LUCD) Q2 2026 earnings summary

Executive summary

• Achieved $1.5 million in Q2 2026 revenue with 2,770 EsoGuard tests performed, within the 2,500–3,000 target range.

• Secured first laboratory benefit manager (LBM) commercial coverage policy from Concert, adopted by multiple health plans, and expanded commercial and VA engagement.

• Advanced health system partnerships, focusing on EHR integration, workflow optimization, and cost-effectiveness modeling.

• Revenue growth driven by increased test adoption, but recurring losses and negative cash flows persist.

• Substantial doubt exists about ability to continue as a going concern without additional capital or expanded reimbursement.

Financial highlights

• Q2 2026 revenue was $1.5 million, up from $1.16 million in Q2 2025; six-month revenue was $2.7 million.

• Cash at quarter end was $33.4 million, flat with year-end; cash position improved sequentially.

• Non-GAAP net loss per share improved to $(0.06), GAAP net loss per share was $(0.08); net loss for Q2 2026 was $14.7 million.

• Operating expenses for Q2 2026 were $14.3 million, including $1.7 million in stock-based compensation.

• Senior secured convertible notes outstanding were $21.975 million principal, $23.5 million fair value as of June 30, 2026.

Outlook and guidance

• Confident in securing a positive Medicare draft LCD, with CMS backlog easing.

• Expect VA contracts to contribute to test volume and revenue in the new budget cycle.

• Maintaining test volume guidance of 2,500–3,000 per quarter, with plans to scale upon broader reimbursement.

• Ongoing negative cash flow and recurring losses expected; future operations depend on raising additional capital and achieving broader reimbursement.

• Anticipate further LBM coverage and expanded commercial payer adoption.